CRLF2, IL7RA, and IL2RG mRNA expression and activation of the JAK-STAT pathway. (A) Fold change of mRNA expression measured by the comparative Ct method of CRLF2 in (i) translocation patient samples (n = 7) compared with control patient cohort (n = 17) without the translocation or deletion (ii). Cell lines (n = 2) with the translocation compared with cell line control cohort (n = 12): RCH-ACV, REH, Per365, 697, 380, Tanoue, LILA-1, SEM, LK63 (BCP-ALL) RAJI, DHL4 (B-cell lymphoma), and HL-60 (acute myeloid leukemia) without the translocation or deletion and (iii) deletion patient samples (n = 5) compared with the same patient control cohort (n = 17). IL7RA and IL2RG mRNA expression measured in (B) 7 patients with the translocation compared with the patient control cohort (C) the cell lines (n = 2) compared with a cell line control cohort. The error bars for the control cohorts indicate the variable expression of all target genes tested. (D) Flow cytometry histogram of control cell lines (RCH-ACV; 697; SEM; JURKAT) and translocation positive cell lines (MHH-CALL-4 and MUTZ5) using a PE-labeled antibody to CRLF2. (E) Western blot showing presence of phosphorylated STAT5 and JAK2 observed in translocation-positive cell lines, MHH-CALL-4 and MUTZ5, compared with other cell lines.